229 related articles for article (PubMed ID: 26180022)
21. Angiotensin II activates Ca
Kashihara T; Nakada T; Kojima K; Takeshita T; Yamada M
J Physiol; 2017 Jul; 595(13):4207-4225. PubMed ID: 28295363
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular angiotensin II type 1 receptor biased signaling: Focus on non-Gq-, non-βarrestin-dependent signaling.
Lymperopoulos A; Borges JI; Carbone AM; Cora N; Sizova A
Pharmacol Res; 2021 Dec; 174():105943. PubMed ID: 34662735
[TBL] [Abstract][Full Text] [Related]
23. Loss of biased signaling at a G protein-coupled receptor in overexpressed systems.
Li A; Liu S; Huang R; Ahn S; Lefkowitz RJ
PLoS One; 2023; 18(3):e0283477. PubMed ID: 36961836
[TBL] [Abstract][Full Text] [Related]
24. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure).
Felker GM; Butler J; Collins SP; Cotter G; Davison BA; Ezekowitz JA; Filippatos G; Levy PD; Metra M; Ponikowski P; Soergel DG; Teerlink JR; Violin JD; Voors AA; Pang PS
JACC Heart Fail; 2015 Mar; 3(3):193-201. PubMed ID: 25650371
[TBL] [Abstract][Full Text] [Related]
25. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.
Takezako T; Unal H; Karnik SS; Node K
Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738
[TBL] [Abstract][Full Text] [Related]
26. Heterotrimeric Gq proteins act as a switch for GRK5/6 selectivity underlying β-arrestin transducer bias.
Kawakami K; Yanagawa M; Hiratsuka S; Yoshida M; Ono Y; Hiroshima M; Ueda M; Aoki J; Sako Y; Inoue A
Nat Commun; 2022 Jan; 13(1):487. PubMed ID: 35078997
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin type 1A receptor regulates β-arrestin binding of the β
Tóth AD; Gyombolai P; Szalai B; Várnai P; Turu G; Hunyady L
Mol Cell Endocrinol; 2017 Feb; 442():113-124. PubMed ID: 27908837
[TBL] [Abstract][Full Text] [Related]
28. Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes.
Delaitre C; Boisbrun M; Lecat S; Dupuis F
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201646
[TBL] [Abstract][Full Text] [Related]
29. Unraveling allostery within the angiotensin II type 1 receptor for Gα
Cao Y; van der Velden WJC; Namkung Y; Nivedha AK; Cho A; Sedki D; Holleran B; Lee N; Leduc R; Muk S; Le K; Bhattacharya S; Vaidehi N; Laporte SA
Sci Signal; 2023 Aug; 16(797):eadf2173. PubMed ID: 37552769
[TBL] [Abstract][Full Text] [Related]
30. Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms.
Bonde MM; Hansen JT; Sanni SJ; Haunsø S; Gammeltoft S; Lyngsø C; Hansen JL
PLoS One; 2010 Nov; 5(11):e14135. PubMed ID: 21152433
[TBL] [Abstract][Full Text] [Related]
31. Genetic code expansion and photocross-linking identify different β-arrestin binding modes to the angiotensin II type 1 receptor.
Gagnon L; Cao Y; Cho A; Sedki D; Huber T; Sakmar TP; Laporte SA
J Biol Chem; 2019 Nov; 294(46):17409-17420. PubMed ID: 31530642
[TBL] [Abstract][Full Text] [Related]
32. β-Arrestin-Biased AT
Kashihara T; Kawagishi H; Nakada T; Numaga-Tomita T; Kadota S; Wolf EE; Du CK; Shiba Y; Morimoto S; Yamada M
JACC Basic Transl Sci; 2020 Nov; 5(11):1057-1069. PubMed ID: 33294739
[TBL] [Abstract][Full Text] [Related]
33. Distinctive Activation Mechanism for Angiotensin Receptor Revealed by a Synthetic Nanobody.
Wingler LM; McMahon C; Staus DP; Lefkowitz RJ; Kruse AC
Cell; 2019 Jan; 176(3):479-490.e12. PubMed ID: 30639100
[TBL] [Abstract][Full Text] [Related]
34. Ezrin, radixin, and moesin phosphorylation in NIH3T3 cells revealed angiotensin II type 1 receptor cell-type-dependent biased signaling.
Ibrahim IA; Nakaya M; Kurose H
J Pharmacol Sci; 2013; 122(1):1-9. PubMed ID: 23575451
[TBL] [Abstract][Full Text] [Related]
35. Mapping Angiotensin II Type 1 Receptor-Biased Signaling Using Proximity Labeling and Proteomics Identifies Diverse Actions of Biased Agonists.
Pfeiffer CT; Wang J; Paulo JA; Jiang X; Gygi SP; Rockman HA
J Proteome Res; 2021 Jun; 20(6):3256-3267. PubMed ID: 33950683
[TBL] [Abstract][Full Text] [Related]
36. First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers.
Soergel DG; Subach RA; Cowan CL; Violin JD; Lark MW
J Clin Pharmacol; 2013 Sep; 53(9):892-9. PubMed ID: 23813302
[TBL] [Abstract][Full Text] [Related]
37. Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations.
Cabana J; Holleran B; Leduc R; Escher E; Guillemette G; Lavigne P
J Biol Chem; 2015 Jun; 290(25):15835-15854. PubMed ID: 25934394
[TBL] [Abstract][Full Text] [Related]
38. Beta-arrestin-mediated signaling in the heart.
Patel PA; Tilley DG; Rockman HA
Circ J; 2008 Nov; 72(11):1725-9. PubMed ID: 18838825
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway.
Diniz GP; Carneiro-Ramos MS; Barreto-Chaves ML
Basic Res Cardiol; 2009 Nov; 104(6):653-67. PubMed ID: 19588183
[TBL] [Abstract][Full Text] [Related]
40. Insights Into the Role of Angiotensin-II AT
Mathieu NM; Nakagawa P; Grobe JL; Sigmund CD
Hypertension; 2024 Jan; 81(1):6-16. PubMed ID: 37449411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
